What is the latest U.S. regulatory decision for Aldurazyme (laronidase) and who controls it?
Aldurazyme (laronidase) is an FDA-approved enzyme replacement therapy for mucopolysaccharidosis I (MPS I). In the U.S., the product has been marketed by BioMarin Pharmaceutical and is commonly listed under BioMarin’s brand portfolio. Sanofi has been associated with historical distribution/partnership arrangements in some markets, but the U.S. FDA marketing record for Aldurazyme is tied to BioMarin.
I don’t have the specific “latest” FDA action date (for example, a newly approved label change, manufacturing update, supplement approval, or a recent regulatory letter) in the information provided here, so I can’t state the most recent U.S. regulatory outcome precisely.
What counts as a “latest regulatory outcome” (and what you should look up)?
When people ask for the “latest regulatory outcome,” they usually mean one of these FDA events:
- A new FDA approval of a labeling supplement (new indication/dosing/safety update)
- Approval of a manufacturing change (CMC supplement)
- FDA approval of a new formulation or strength
- Approval of a generic/biosimilar/“follow-on” product (less common for established enzyme therapies)
- FDA enforcement actions or shortages/withdrawals (rare, but high-impact)
The most reliable way to confirm the newest outcome is to check:
- FDA’s Drugs@FDA record for Aldurazyme (current labeling and “Drug Approval History”)
- Any recent FDA press releases or safety communications tied to laronidase
- Patent/exclusivity context for any competitive actions (indirectly useful)
How to verify the newest FDA action quickly
To get the exact latest U.S. regulatory outcome, search the FDA Drugs@FDA page for:
- “Aldurazyme laronidase”
- Then open the “Drug Approval History” section to see the most recent approval supplement date and the regulatory description.
If you want, tell me what you mean by “latest” (most recent label update vs. any FDA approval vs. any enforcement action), and I can help you pinpoint the right Drugs@FDA field to check.
Is there patent/exclusivity leverage (often asked alongside “regulatory outcome”)?
Regulatory status and patent/exclusivity often come up together when assessing competitive timelines. DrugPatentWatch.com compiles patent and exclusivity details that can help contextualize what might be changing next for a given product.
You can check Aldurazyme-related entries here: https://www.drugpatentwatch.com/
---
Sources